Shi‐He Liu

553 total citations
26 papers, 394 citations indexed

About

Shi‐He Liu is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Shi‐He Liu has authored 26 papers receiving a total of 394 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 10 papers in Surgery and 10 papers in Oncology. Recurrent topics in Shi‐He Liu's work include Pancreatic function and diabetes (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Metabolism, Diabetes, and Cancer (5 papers). Shi‐He Liu is often cited by papers focused on Pancreatic function and diabetes (10 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Metabolism, Diabetes, and Cancer (5 papers). Shi‐He Liu collaborates with scholars based in United States, China and Italy. Shi‐He Liu's co-authors include F. Charles Brunicardi, John Nemunaitis, Nikiforos Ballian, Justin F. Creeden, Guisheng Zhou, Juehua Yu, Marie‐Claude Gingras, Richard A. Gibbs, William Fisher and Andrea L. Nestor‐Kalinoski and has published in prestigious journals such as PLoS ONE, Cancer and The FASEB Journal.

In The Last Decade

Shi‐He Liu

25 papers receiving 387 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shi‐He Liu United States 14 219 116 115 77 55 26 394
Xiaohuan Gao United States 9 303 1.4× 166 1.4× 85 0.7× 93 1.2× 54 1.0× 15 538
Hellen Kuasne Brazil 14 323 1.5× 157 1.4× 111 1.0× 107 1.4× 56 1.0× 24 615
Angela M. Farrelly Ireland 10 256 1.2× 125 1.1× 62 0.5× 55 0.7× 29 0.5× 19 417
Cristina Sáiz-Ladera Spain 15 363 1.7× 219 1.9× 103 0.9× 151 2.0× 36 0.7× 28 638
Maithao Le United States 12 231 1.1× 175 1.5× 69 0.6× 46 0.6× 46 0.8× 22 466
Laura Wilson United Kingdom 13 345 1.6× 150 1.3× 78 0.7× 105 1.4× 33 0.6× 23 563
Priyanka Tibarewal United Kingdom 7 425 1.9× 72 0.6× 94 0.8× 71 0.9× 49 0.9× 11 486
Esra Dikoglu United States 10 232 1.1× 111 1.0× 75 0.7× 70 0.9× 37 0.7× 14 402
Xiaoli Xu China 11 262 1.2× 89 0.8× 38 0.3× 84 1.1× 46 0.8× 20 385
Wenping Li China 12 301 1.4× 108 0.9× 96 0.8× 101 1.3× 25 0.5× 38 513

Countries citing papers authored by Shi‐He Liu

Since Specialization
Citations

This map shows the geographic impact of Shi‐He Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐He Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐He Liu more than expected).

Fields of papers citing papers by Shi‐He Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shi‐He Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐He Liu. The network helps show where Shi‐He Liu may publish in the future.

Co-authorship network of co-authors of Shi‐He Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Shi‐He Liu. A scholar is included among the top collaborators of Shi‐He Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shi‐He Liu. Shi‐He Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
2.
Liu, Shi‐He, et al.. (2024). The Role of Heat Shock Factor 1 in Preserving Proteomic Integrity During Copper-Induced Cellular Toxicity. International Journal of Molecular Sciences. 25(21). 11657–11657. 3 indexed citations
3.
Creeden, Justin F., Jian‐Ting Zhang, Yakov Lapitsky, et al.. (2024). Smart exosomes enhance PDAC targeted therapy. Journal of Controlled Release. 368. 413–429. 32 indexed citations
4.
Liu, Shi‐He, Juehua Yu, Justin F. Creeden, et al.. (2020). Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. Cancer Letters. 491. 97–107. 18 indexed citations
5.
Chen, Cheng, Hongjin Wu, Yu Xu, et al.. (2020). Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. Oncology Reports. 44(6). 2569–2580. 14 indexed citations
6.
Creeden, Justin F., Khaled Alganem, Ali Sajid Imami, et al.. (2020). Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases. International Journal of Molecular Sciences. 21(22). 8679–8679. 27 indexed citations
7.
Liu, Shi‐He, Justin F. Creeden, John Nemunaitis, et al.. (2019). BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Cancer Letters. 457. 10–19. 18 indexed citations
8.
Liu, Shi‐He, Juehua Yu, Xiaochen Liu, et al.. (2018). A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. Cancer Letters. 418. 75–83. 11 indexed citations
9.
Yu, Juehua, et al.. (2016). PDX1 associated therapy in translational medicine. Annals of Translational Medicine. 4(11). 214–214. 16 indexed citations
10.
Wu, James X., Shi‐He Liu, John Nemunaitis, & F. Charles Brunicardi. (2015). Liposomal insulin promoter–thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice. Cancer Letters. 359(2). 206–210. 9 indexed citations
12.
Liu, Shi‐He, Donald D. Rao, John Nemunaitis, et al.. (2012). PDX-1 Is a Therapeutic Target for Pancreatic Cancer, Insulinoma and Islet Neoplasia Using a Novel RNA Interference Platform. PLoS ONE. 7(8). e40452–e40452. 25 indexed citations
13.
Rajput, Padmesh S., Geetanjali Kharmate, Michael A. Norman, et al.. (2011). Somatostatin Receptor 1 and 5 Double Knockout Mice Mimic Neurochemical Changes of Huntington's Disease Transgenic Mice. PLoS ONE. 6(9). e24467–e24467. 24 indexed citations
14.
Nemunaitis, John, Donald D. Rao, Shi‐He Liu, & F. Charles Brunicardi. (2011). Personalized Cancer Approach: Using RNA Interference Technology. World Journal of Surgery. 35(8). 1700–1714. 7 indexed citations
15.
Liu, Shi‐He, Sanjeet Patel, Marie‐Claude Gingras, et al.. (2010). PDX‐1. Cancer. 117(4). 723–733. 36 indexed citations
16.
Patel, Sanjeet, Guisheng Zhou, Shi‐He Liu, et al.. (2009). Microarray Analysis of Somatostatin Receptor 5‐Regulated Gene Expression Profiles in Murine Pancreas. World Journal of Surgery. 33(4). 630–7. 8 indexed citations
17.
Ballian, Nikiforos, Shi‐He Liu, & F. Charles Brunicardi. (2008). Transcription factor PDX-1 in human colorectal adenocarcinoma: A potential tumor marker?. World Journal of Gastroenterology. 14(38). 5823–5823. 14 indexed citations
18.
Fagan, Shawn P., Nikiforos Ballian, Shi‐He Liu, et al.. (2007). PDX-1 Expression Is Associated with Islet Proliferation In Vitro and In Vivo. Journal of Surgical Research. 144(1). 8–16. 27 indexed citations
19.
Ballian, Nikiforos, Min Hu, Shi‐He Liu, & F. Charles Brunicardi. (2007). Proliferation, Hyperplasia, Neogenesis, and Neoplasia in the Islets of Langerhans. Pancreas. 35(3). 199–206. 10 indexed citations
20.
Ballian, Nikiforos, et al.. (2006). Cytotoxic Gene Therapy for Human Breast Cancer In Vitro. Journal of Surgical Research. 136(1). 154–160. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026